These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34195886)

  • 1. HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy.
    Arora S; Catania R; Borhani A; Horvat N; Fowler K; Harmath C
    Abdom Radiol (NY); 2021 Aug; 46(8):3686-3697. PubMed ID: 34195886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the role of radiologists in complex treatment decisions for patients with hepatocellular carcinoma.
    Kamal O; Horvat N; Arora S; Chaudhry H; Elmohr M; Khanna L; Nepal PS; Wungjramirun M; Nandwana SB; Shenoy-Bhangle AS; Lee J; Kielar A; Marks R; Elsayes K; Fung A
    Abdom Radiol (NY); 2023 Dec; 48(12):3677-3687. PubMed ID: 37715846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to Loco-Regional Therapy Predicts Outcomes After Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma.
    Antwi SO; Habboush YY; Chase LA; Lee DD; Patel T
    Ann Hepatol; 2018 Oct; 17(6):969-979. PubMed ID: 30600299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional Therapy.
    Wallace MC; Sek K; Francis RJ; Samuelson S; Ferguson J; Tibballs J; Asad A; Preen DB; MacQuillan G; Garas G; Adams LA; Jeffrey GP
    Dig Dis Sci; 2020 Feb; 65(2):647-657. PubMed ID: 31440998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.
    Kielar A; Fowler KJ; Lewis S; Yaghmai V; Miller FH; Yarmohammadi H; Kim C; Chernyak V; Yokoo T; Meyer J; Newton I; Do RK
    Abdom Radiol (NY); 2018 Jan; 43(1):218-230. PubMed ID: 28780679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
    Gordic S; Corcuera-Solano I; Stueck A; Besa C; Argiriadi P; Guniganti P; King M; Kihira S; Babb J; Thung S; Taouli B
    J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical review of HCC imaging in the multidisciplinary setting: treatment allocation and evaluation of response.
    Amorim J; França M; Perez-Girbes A; Torregrosa A; Martí-Bonmatí L
    Abdom Radiol (NY); 2020 Oct; 45(10):3119-3128. PubMed ID: 32173774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI features of treated hepatocellular carcinoma following locoregional therapy: a pictorial review.
    Alnammi M; Wortman J; Therrien J; Afnan J
    Abdom Radiol (NY); 2022 Jul; 47(7):2299-2313. PubMed ID: 35524803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of 18F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma.
    Mena E; Shih J; Chung JY; Jones J; Rabiee A; Monge C; Turkbey B; Lindenberg L; Salerno KE; Kassin M; Wood B; Hernandez J; Maass-Moreno R; Saboury B; Jakhete N; Molitoris JK; Unger KR; Choyke PL; Escorcia FE
    PLoS One; 2022; 17(11):e0277407. PubMed ID: 36367894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation and Prediction of Treatment Response for Hepatocellular Carcinoma.
    Tsujita Y; Sofue K; Ueshima E; Ueno Y; Hori M; Tsurusaki M; Murakami T
    Magn Reson Med Sci; 2023 Apr; 22(2):209-220. PubMed ID: 36792205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of post-TACE necrosis of hepatocellular carcinoma usingvolumetric enhancement on MRI and volumetric oil deposition on CT, with pathological correlation.
    Najmi Varzaneh F; Pandey A; Aliyari Ghasabeh M; Shao N; Khoshpouri P; Pandey P; Zarghampour M; Fouladi D; Liddell R; Anders RA; Kamel IR
    Eur Radiol; 2018 Jul; 28(7):3032-3040. PubMed ID: 29383518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges of advanced hepatocellular carcinoma.
    Colagrande S; Inghilesi AL; Aburas S; Taliani GG; Nardi C; Marra F
    World J Gastroenterol; 2016 Sep; 22(34):7645-59. PubMed ID: 27678348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment.
    Kim MN; Kim BK; Han KH; Kim SU
    Expert Rev Gastroenterol Hepatol; 2015 Mar; 9(3):335-48. PubMed ID: 25370168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging After Locoregional Therapy for Hepatocellular Carcinoma with Emphasis on LIRADS Treatment Response Assessment Criteria.
    Bajaj G; Sundaram K; Jambhekar K; Ram R
    Semin Ultrasound CT MR; 2021 Aug; 42(4):318-331. PubMed ID: 34130846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy.
    Gross A; Albrecht T
    Cardiovasc Intervent Radiol; 2020 Mar; 43(3):402-410. PubMed ID: 31705244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma.
    Chen G; Ma DQ; He W; Zhang BF; Zhao LQ
    World J Gastroenterol; 2008 Oct; 14(37):5738-43. PubMed ID: 18837093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort.
    Sandow T; Pavlus J; Field D; Lacayo E; Cohen E; Lynskey G; Caridi T; Buckley D; Cardella J; Kallakury B; Spies J; Kim AY
    J Vasc Interv Radiol; 2019 Jul; 30(7):995-1003. PubMed ID: 31109853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study.
    El-Serag HB; Siegel AB; Davila JA; Shaib YH; Cayton-Woody M; McBride R; McGlynn KA
    J Hepatol; 2006 Jan; 44(1):158-66. PubMed ID: 16290309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Volume Doubling Time as a Dynamic Prognostic Marker for Patients with Hepatocellular Carcinoma.
    Kim JK; Kim HD; Jun MJ; Yun SC; Shim JH; Lee HC; Lee D; An J; Lim YS; Chung YH; Lee YS; Kim KM
    Dig Dis Sci; 2017 Oct; 62(10):2923-2931. PubMed ID: 28815349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updated treatment approach to hepatocellular carcinoma.
    Llovet JM
    J Gastroenterol; 2005 Mar; 40(3):225-35. PubMed ID: 15830281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.